Summary
Eli Lilly and Company's Q2 2003 report shows a solid increase in net sales, up 11% year-over-year for the quarter, driven by strong performances in key products like Zyprexa, Humalog, Gemzar, and Evista, as well as the launch of Strattera. While the company reported a 5% increase in net income for the quarter, the six-month period saw a 15% decrease primarily due to significant asset impairments, restructuring, and other special charges totaling $353.9 million incurred in the first quarter. These charges related to streamlining operations, manufacturing asset impairments, and impairments associated with an investment in Isis Pharmaceuticals. The company is actively managing its financial resources, evidenced by the continued execution of its $3.0 billion share repurchase program and an increase in long-term debt to fund strategic initiatives and refinance existing debt. Lilly is also navigating several significant legal challenges, including patent litigation concerning Zyprexa and Evista, and product liability lawsuits, while also managing manufacturing quality improvement initiatives with the FDA. Despite these challenges and the impact of one-time charges, the company maintains a positive outlook with expectations for continued low double-digit sales growth for the full year 2003.
Key Highlights
- 1Net sales increased by 11% to $3.09 billion in Q2 2003 compared to Q2 2002, driven by strong sales of Zyprexa, Humalog, Gemzar, and Evista, and the launch of Strattera.
- 2Net income for Q2 2003 rose 5% to $692.2 million ($0.64 per share), but net income for the first six months of 2003 decreased 15% to $1.099 billion ($1.02 per share) year-over-year.
- 3The first quarter of 2003 included $353.9 million in asset impairments, restructuring, and other special charges, which significantly impacted the year-to-date net income and EPS.
- 4Worldwide sales of Zyprexa increased 15% in Q2 2003 and 16% for the first six months, despite some competitive pressures in the U.S.
- 5Strattera, launched in January 2003, achieved sales of $74.8 million in Q2 and $129.7 million in the first six months, exceeding initial expectations.
- 6The company is actively engaged in share repurchases, having bought back approximately $281.1 million of stock in the first half of 2003 as part of its $3.0 billion program.
- 7Significant legal proceedings are ongoing, including patent litigation for Zyprexa and Evista, and product liability claims, which could have a material adverse impact.